{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:24:58Z","timestamp":1787221498965,"version":"build-2736575974"},"reference-count":159,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.kint.2026.02.045","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:17:44Z","timestamp":1781626664000},"page":"583-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of the kidney in glucose homeostasis: the basis for pharmacotherapy and prevention of cardiorenal complications in diabetes"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-0208","authenticated-orcid":false,"given":"Eugenio","family":"Cersosimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.02.045_bib1","series-title":"Endocrinology","first-page":"673","article-title":"Regulation of intermediary metabolism during fasting and refeeding","author":"DeFronzo","year":"2015"},{"key":"10.1016\/j.kint.2026.02.045_bib2","series-title":"A study of prolonged fasting","author":"Benedict","year":"1915"},{"key":"10.1016\/j.kint.2026.02.045_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/ajplegacy.1938.124.2.279","article-title":"The relationship of kidney function to the glucose utilization of the extra-abdominal tissues","volume":"124","author":"Bergman","year":"1938","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib4","article-title":"Starvation in man","volume":"282","author":"Cahill","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"9","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.kint.2026.02.045_bib6","article-title":"Human glucose transporters in renal glucose homeostasis","volume":"22","author":"Edzikowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.02.045_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose co-transporter SGLT2: delineation of the major renal resorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/00365517109090667","article-title":"Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ki.1989.203","article-title":"Sodium-coupled amino acid transport in renal tubule","volume":"36","author":"Zelikovic","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib10","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2337\/db10-1667","article-title":"Learning from glycosuria","volume":"60","author":"Ferrannini","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejogrb.2010.02.032","article-title":"Physiology and clinical value of glycosuria after a glucose challenge during pregnancy","volume":"150","author":"Coolen","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.kint.2026.02.045_bib13","first-page":"92","article-title":"Glucosuria is not always due to diabetes","volume":"38","author":"Lewis","year":"2021","journal-title":"Fed Pract"},{"key":"10.1016\/j.kint.2026.02.045_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome","volume":"12","author":"Van Bommel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1113\/EP085670","article-title":"Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane","volume":"101","author":"Chichger","year":"2016","journal-title":"Exp. Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1113\/jphysiol.2007.130906","article-title":"Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT-2","volume":"582","author":"Mace","year":"2007","journal-title":"J Physiol"},{"issue":"6","key":"10.1016\/j.kint.2026.02.045_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1113\/EP085816","article-title":"Renal glucose transporters \u201csweeten\u201d the pot","volume":"101","author":"Wong","year":"2016","journal-title":"Exp Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ki.1976.26","article-title":"Sites of enzyme activity along the nephron","volume":"9","author":"Schmidt","year":"1976","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib20","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1172\/JCI117270","article-title":"Insulin regulation of renal glucose metabolism in conscious dogs","volume":"93","author":"Cersosimo","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s001250050745","article-title":"Renal glucose production and utilization: new aspects in humans","volume":"40","author":"Stumvoll","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.02.045_bib22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/diabetes.49.7.1186","article-title":"Renal substrate metabolism and gluconeogenesis during hypoglycemia in humans","volume":"49","author":"Cersosimo","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2337\/diacare.24.2.382","article-title":"Renal gluconeogenesis: its importance in human glucose homeostasis","volume":"24","author":"Gerich","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.02.045_bib24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1203\/00006450-198309000-00017","article-title":"Renal glycogen content and hormonal control of enzymes involved in renal glycogen metabolism","volume":"17","author":"Delaval","year":"1983","journal-title":"Pediatr Res"},{"key":"10.1016\/j.kint.2026.02.045_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ki.1986.8","article-title":"Glucose metabolism in renal tubular function","volume":"29","author":"Ross","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib26","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1152\/ajpendo.1999.276.1.E78","article-title":"Insulin regulation of renal glucose metabolism in humans","volume":"276","author":"Cersosimo","year":"1999","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2337\/diabetes.48.2.261","article-title":"Renal glucose production during insulin-induced hypoglycemia in humans","volume":"48","author":"Cersosimo","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1172\/JCI106016","article-title":"Liver and kidney: metabolism during prolonged starvation","volume":"48","author":"Owen","year":"1969","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib29","doi-asserted-by":"crossref","first-page":"E622","DOI":"10.1152\/ajpendo.1986.250.6.E622","article-title":"Role of glutamine in adaptations in nitrogen metabolism during fasting","volume":"250","author":"Cersosimo","year":"1986","journal-title":"A J Physiol Endocrinol Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diabetes.48.2.292","article-title":"Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting","volume":"48","author":"Ekberg","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1172\/JCI105375","article-title":"Renal gluconeogenesis in acidosis, alkalosis and potassium deficiency: its possible role in the regulation of renal ammonia production","volume":"45","author":"Goodman","year":"1966","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI2415","article-title":"Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus","volume":"102","author":"Meyer","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJM198611133152002","article-title":"Hypoglycemia in hospitalized patients","volume":"315","author":"Fischer","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/diabetes.49.3.450","article-title":"Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation","volume":"49","author":"Joseph","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2337\/diab.45.7.891","article-title":"Glucose-6-phosphatase mRNA and activity are increased to the same extent in kidney and liver of diabetic rats","volume":"45","author":"Mithieux","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib37","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1002\/jcp.27598","article-title":"Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions","volume":"234","author":"Swe","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib38","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib39","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.diabres.2008.11.003","article-title":"Enhanced expressions of sodium-glucose co-transporters in the kidneys of diabetic Zucker rats","volume":"83","author":"Tabatabai","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kint.2026.02.045_bib40","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/dom.13003","article-title":"Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects","volume":"19","author":"Norton","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib41","first-page":"81","article-title":"Renal glucose handling and the kidney as a target for anti-diabetic medication","volume":"7","author":"Cersosimo","year":"2014","journal-title":"Curr Trends Endocrinol"},{"key":"10.1016\/j.kint.2026.02.045_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1440-1681.12034","article-title":"Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension","volume":"40","author":"Hansell","year":"2013","journal-title":"Clin Expl Pharm Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1523-1755.1999.00271.x","article-title":"Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells","volume":"55","author":"Zhang","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ncpneph0757","article-title":"Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy","volume":"4","author":"Singh","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000208211","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of hyperglycemia and tubular transport","volume":"111","author":"Vallon","year":"2009","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00422325","article-title":"Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment","volume":"11","author":"Mogensen","year":"1975","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.02.045_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ki.1992.127","article-title":"Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus","volume":"41","author":"Vora","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib50","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1073\/pnas.90.5.1814","article-title":"Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy","volume":"90","author":"Yamamoto","year":"1993","journal-title":"Proc Natl Acad. Sci U S A"},{"key":"10.1016\/j.kint.2026.02.045_bib51","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1046\/j.1523-1755.1999.00721.x","article-title":"The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?","volume":"56","author":"Gilbert","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ackd.2005.01.008","article-title":"Tubular changes in early diabetic nephropathy","volume":"12","author":"Thomas","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.045_bib53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1055\/s-0029-1220752","article-title":"Role of growth factors in diabetic kidney disease","volume":"41","author":"Chiarelli","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.kint.2026.02.045_bib54","doi-asserted-by":"crossref","first-page":"F887","DOI":"10.1152\/ajprenal.00050.2001","article-title":"Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function","volume":"281","author":"Basile","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MNH.0000000000000341","article-title":"Hypoxia-inducible factor activation in diabetic kidney disease","volume":"26","author":"Persson","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2026.02.045_bib56","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2174\/138161208784139710","article-title":"Role of AGEs in diabetic nephropathy","volume":"14","author":"Fukagami","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.kint.2026.02.045_bib57","series-title":"Endotext","article-title":"Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes","author":"Feingold","year":"2000"},{"key":"10.1016\/j.kint.2026.02.045_bib58","series-title":"Antihypertensive medications","author":"Khalil","year":"2025"},{"key":"10.1016\/j.kint.2026.02.045_bib59","first-page":"S1","article-title":"Standards of care in diabetes \u2013 2025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"4S","key":"10.1016\/j.kint.2026.02.045_bib60","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib61","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of diabetes mellitus in patients with CKD; core curriculum 2022","volume":"79","author":"Hahr","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.045_bib62","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib63","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"Prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease","volume":"44","author":"UKPDS trial","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib64","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib65","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links: the Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.02.045_bib66","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177625","article-title":"SGLT2 inhibitors: cardiorenal metabolic drugs for the ages","volume":"134","author":"DeFronzo","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib69","first-page":"1402","article-title":"Empagliflozin improves beta cell function measured with the hyperglycemic clamp in T2DM","volume":"103","author":"Al-Jobori","year":"2018","journal-title":"J Clin Endo Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib70","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2174\/1573399814666180813124645","article-title":"Hormonal, metabolic and hemodynamic adaptations to glycosuria in type 2 diabetes patients treated with sodium-glucose co-transporter inhibitors","volume":"15","author":"Cersosimo","year":"2019","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.kint.2026.02.045_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib72","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41440-024-01723-6","article-title":"The relationship between SGLT2 and systemic blood pressure regulation","volume":"47","author":"Ahwin","year":"2024","journal-title":"Hypertension Res"},{"key":"10.1016\/j.kint.2026.02.045_bib73","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib74","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib76","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/FJC.0000000000001511","article-title":"The role of SGLT2 inhibitors on heart failure outcomes in nondiabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"83","author":"Kommu","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.kint.2026.02.045_bib78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib79","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Vlado","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib80","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib82","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.12970","article-title":"Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes","volume":"19","author":"Solini","year":"2017","journal-title":"Diabetes Obe Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib83","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.02.045_bib84","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib86","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/clinem\/dgad438","article-title":"Emergence of a new glucoregulatory mechanism for glycemic control with dapagliflozin\/exenatide therapy in type 2 diabetes","volume":"109","author":"Cersosimo","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib88","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/db23-0457","article-title":"Effect of dapagliflozin on renal and hepatic glucose kinetics in T2DM and NGT subjects","volume":"73","author":"Chen","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib89","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2337\/db19-0770","article-title":"Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors","volume":"69","author":"Alatrach","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib90","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2337\/dc19-1993","article-title":"Clinical parameters, fuel oxidation and glucose kinetics in type 2 diabetes patients treated with dapagliflozin plus saxagliptin","volume":"43","author":"Qin","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.02.045_bib91","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2i and diabetic keto-acidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.kint.2026.02.045_bib92","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.02.045_bib93","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/nu13051580","article-title":"Sugar or fat? renal tubular metabolism reviewed in health and disease","volume":"13","author":"Hewing","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.kint.2026.02.045_bib94","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1172\/JCI105650","article-title":"Brain metabolism during fasting","volume":"46","author":"Owen","year":"1967","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.kint.2026.02.045_bib95","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on water and sodium metabolism","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2026.02.045_bib96","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib97","doi-asserted-by":"crossref","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2i on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.02.045_bib98","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium\u2013glucose co-transporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.02.045_bib99","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.kint.2026.02.045_bib100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-022-01492-x","article-title":"Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial","volume":"21","author":"Van Ruiten","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2026.02.045_bib101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with T2D in the randomized, double-blind RED trial","volume":"97","author":"Van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib102","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/dom.16094","article-title":"Effect of dapagliflozin on renal hemodynamics in hyperfiltering T2D patients","volume":"27","author":"Cersosimo","year":"2025","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib103","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter-2 inhibition in patients with type 1 diabetes","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.02.045_bib104","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/ndt\/10.9.1644","article-title":"Age as a determinant of glomerular filtration rate in non-insulin-dependent diabetes mellitus","volume":"10","author":"Rius","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.045_bib105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11357-019-00122-x","article-title":"Assessment of age-related decline of neurovascular coupling responses by functional near-infrared spectroscopy (fNIRS) in humans","volume":"41","author":"Csipo","year":"2019","journal-title":"Geroscience"},{"key":"10.1016\/j.kint.2026.02.045_bib106","doi-asserted-by":"crossref","first-page":"676","DOI":"10.14336\/AD.2019.0315","article-title":"A microcirculatory theory of aging","volume":"10","author":"Jin","year":"2019","journal-title":"Aging Dis"},{"key":"10.1016\/j.kint.2026.02.045_bib107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2019.09.023","article-title":"Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?","volume":"97","author":"Bjornstad","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib108","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s12325-019-01054-w","article-title":"Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"36","author":"Handelsman","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.kint.2026.02.045_bib109","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.kint.2026.02.045_bib110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.kint.2026.02.045_bib112","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00417-023-06273-0","article-title":"SGLT2 inhibitors and diabetic retinopathy progression","volume":"262","author":"Nadelmann","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.kint.2026.02.045_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.926717","article-title":"The outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetes-associated neuropathy: a systematic review and meta-analysis","volume":"13","author":"Kandeel","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2026.02.045_bib122","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.02.045_bib124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000089091","article-title":"Acute and chronic regulation of the renal Na\/H+ exchanger NHE3 in rats with STZ-induced diabetes mellitus","volume":"102","author":"Klisic","year":"2006","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib125","doi-asserted-by":"crossref","first-page":"F91","DOI":"10.1152\/ajprenal.2000.278.1.F91","article-title":"High glucose induces the activity and expression of Na (+)\/H (+) exchange in glomerular mesangial cells","volume":"278","author":"Ganz","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib126","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","article-title":"MAP17 is a necessary activator of renal Na+\/glucose cotransporter SGLT2","volume":"28","author":"Coady","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib127","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI12066","article-title":"Hypertrophy and hyperfunction of the diabetic kidney","volume":"107","author":"Hostetter","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.045_bib128","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJM199106063242304","article-title":"Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus","volume":"324","author":"Tuttle","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.045_bib129","first-page":"S74","article-title":"Progressive renal disease: the chronic hypoxia hypothesis","volume":"65","author":"Fine","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2026.02.045_bib130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes: mechanism and functional implications","volume":"43","author":"Korner","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.02.045_bib131","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.045_bib132","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib133","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.kint.2026.02.045_bib134","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","article-title":"Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease","volume":"2","author":"de Vries","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2026.02.045_bib135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11892-005-0053-9","article-title":"Lipids and diabetic renal disease","volume":"5","author":"Cooper","year":"2005","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.kint.2026.02.045_bib136","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.02510213","article-title":"The modern spectrum of renal biopsy findings in patients with diabetes","volume":"8","author":"Sharma","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib137","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cmet.2010.08.015","article-title":"Insulin signaling to the glomerular podocyte is critical for normal kidney function","volume":"12","author":"Welsh","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib138","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.kint.2019.07.013","article-title":"Podocyte lipotoxicity in diabetic kidney disease","volume":"96","author":"Nishi","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib139","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2026.02.045_bib140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/MCB.05603-11","article-title":"Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle","volume":"32","author":"Jheng","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2026.02.045_bib141","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1681\/ASN.2013020126","article-title":"Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.045_bib142","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ki.2012.441","article-title":"Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology","volume":"83","author":"Zhan","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.045_bib143","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy","volume":"317","author":"Lee","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib144","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.kint.2026.02.045_bib146","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/dom.13441","article-title":"Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats","volume":"20","author":"Jaikumkao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib147","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.02.045_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.02.045_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells: renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.02.045_bib150","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","article-title":"Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis","volume":"55","author":"Vlachopoulos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2026.02.045_bib151","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1232583","article-title":"Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis","volume":"2018","author":"Batzias","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.kint.2026.02.045_bib152","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.kint.2026.02.045_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.02.045_bib154","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2021.02.057","article-title":"Therapeutic manipulation of myocardial metabolism: state-of-the-art review","volume":"77","author":"Honka","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2026.02.045_bib155","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2026.02.045_bib156","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1096\/fasebj.9.8.7768357","article-title":"Insulin, ketone bodies, and mitochondrial energy transduction","volume":"9","author":"Sato","year":"1995","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2026.02.045_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.kint.2026.02.045_bib158","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.kint.2026.02.045_bib159","article-title":"SGLT2 inhibitors activate pantothenate kinase in the human heart","author":"Forelli","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.kint.2026.02.045_bib160","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packe","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.kint.2026.02.045_bib161","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na (+) through inhibition of the cardiac Na (+)\/H (+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.02.045_bib162","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.kint.2026.02.045_bib163","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.kint.2026.02.045_bib164","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.14885","article-title":"Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes","volume":"25","author":"Moody","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.02.045_bib165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2026.02.045_bib166","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.carpath.2005.01.005","article-title":"Cardiac remodeling and failure from molecules to man (part II)","volume":"14","author":"Fedak","year":"2005","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.kint.2026.02.045_bib167","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.kint.2026.02.045_bib168","article-title":"Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG outcome","volume":"33","author":"Kang","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.kint.2026.02.045_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015078","article-title":"mTORC1 and SGLT2 inhibitors-a therapeutic perspective for diabetic cardiomyopathy","volume":"24","author":"Saha","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826004746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826004746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:45:31Z","timestamp":1787219131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826004746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0085253826004746"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.045","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the kidney in glucose homeostasis: the basis for pharmacotherapy and prevention of cardiorenal complications in diabetes","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}